Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAthelney Tst. Regulatory News (ATY)

Share Price Information for Athelney Tst. (ATY)

Share Price is delayed by 15 minutes
Get Live Data
165.00    0.00 (0.00%)
Bid:
140.00
Ask:
190.00
Spread: 50.00 (35.714%)
Market Cap: £3.56m
ATY Live PriceLast checked at - London Stock Exchange

Intraday Athelney Tst. Share Chart

Net Asset Value(s)

3 Sep 2020 10:49

RNS Number : 9670X
Athelney Trust PLC
03 September 2020
 

Athelney Trust PLC

 

Legal Entity Identifier:

213800ON67TJC7F4DL05

The unaudited net asset value of Athelney Trust was 235.4p at 31 August 2020.

Fund Manager's comment for August 2020

In last month's commentary we noted that besides the fact that global GDP had contracted in the second quarter as a result of COVID-19, the worst appeared to be over. This was confirmed in recent data releases which indicated that while Europe's August PMI surveys were mixed, those for the U.K. had firmed, including being the strongest reading for the Services PMI since 2013. However, in an economy responding to targeted stimuli by the Government, this can be misleading and mask underlying structural issues and competitive pressures on the profitability of some businesses.

 

We continued to realign the portfolio by selling out of our position in Costain, having recently added YouGov and Clinigen into the portfolio. YouGov is an international research and data analytics group headquartered in London which collects and stores data from a proprietary global panel of over 8 million people on consumer opinions, attitudes and behaviour every day. This data is then analysed and used to provide insights that enable intelligent decision-making and improves a wide spectrum of marketing activities for a customer-base which includes media owners, brands and media agencies.

 

Clinigen Group plc is a global business with supply and distribution hubs in key long-term growth regions on five continents and in 14 countries. It is focused on providing ethical access to medicines in the three areas of; global medicine supply; clinical trial, unlicensed and licensed medicines.

During the past month the MSCI World Index and the S&P 500 were up by 6.5% and 7.1% in US$ respectively, driven by the continued rise in the large tech stocks and the FAANGS in particular. The UK market under-performed the global indices with those UK indices associated with smaller companies faring much better as has been the case in recent months. The FTSE 100 was up by 0.5%, the Small Cap Index was up by 3.4%, while the Fledgling Index was up by 3.7% for the month and the AIM All Share Index produced an amazing performance, increasing by 8.9%.

While our overall performance was dragged down by our 29% exposure to property, we are nevertheless pleased with the overall performance of our portfolio which was up by 2.8% during the month. After providing for the company expenses the net performance as reflected in the NAV was an increase of 2.7%.

Cash was conserved to pay the dividend, comprising 4.6% of the portfolio at month end.

 

Fact Sheet

An accompanying fact sheet which includes the information above as well as wider details on the portfolio can be found on the Fund's website www.athelneytrust.co.uk under "About">"Latest Monthly Fact Sheet"

Background Information

Dr. Emmanuel (Manny) Pohl AM

Manny is Chairman and Chief Investment Officer of E C Pohl & Co ("ECP"), an investment management company and has been a major shareholder in Athelney trust for many years.

E C Pohl & co is licensed by the Australian Financial services (licence no.421704).

www.ecpohl.com

www.ecpam.com

Manny Pohl and the ECP group has over AU$1500m under its management including four listed investment companies, three listed in Australia and one in the UK:

· Flagship Investments (ASX code:FSI)

AUD50m https://flagshipinvestments.com.au

· Barrack St Investments (ASX code: BST)

AUD25m www.barrackst.com

· Global Masters Fund Limited (ASX code: GFL)

AUD25m www.globalmastersfund.com.au

· Athelney Trust plc (LSE code: ATY)

GBP5m www.athelneytrust.co.uk

Athelney Trust plc Investment Policy

 The investment objective of the Trust is to provide shareholders with prospects of long-term capital growth with the risks inherent in small cap investment minimised through a spread of holdings in quality small cap companies that operate in various industries and sectors. The Fund Manager also considers that it is important to maintain a progressive dividend record.

The assets of the Trust are allocated predominantly to companies with either a full listing on the London Stock Exchange or a trading facility on AIM or ISDX. The assets of the Trust have been allocated in two main ways: first, to the shares of those companies which have grown steadily over the years in terms of profits and dividends but, despite this progress, the market rating is favourable when compared to future earnings and dividends; second, to those companies whose shares are standing at a favourable level compared with the value of land, buildings or cash in the balance sheet.

Athelney Trust was founded in 1994. In 1996 it was one of the ten pioneer members of the Alternative Investment Market ("AIM"). In 2008 the shares became fully listed on the main market of the London Stock Exchange. Athelney Trust has a successful progressive dividend growth record and the dividend has grown every year since 2004. According to the Association of Investment Companies (AIC) Athelney Trust is one of only "22 investment companies that have increased their dividend every year between 10 and 20 years - the next generation of dividend heroes" (as at 23/03/20). See link

www.theaic.co.uk/aic/news/press-releases/the-next-generation-of-dividend-heroes

Website

www.athelneytrust.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGCGDCCSGDGGX
Date   Source Headline
3rd Jun 20267:22 amRNSNet Asset Value(s)
6th May 20267:35 amRNSNet Asset Value(s)
16th Apr 20268:50 amRNSAGM Statement
7th Apr 20267:00 amRNSNet Asset Value(s)
3rd Mar 20263:15 pmRNSAnnual Financial Report
3rd Mar 202612:09 pmRNSNet Asset Value(s)
3rd Feb 20268:27 amRNSNet Asset Value(s)
5th Jan 20269:53 amRNSNet Asset Value(s)
2nd Dec 202510:41 amRNSNet Asset Value(s)
4th Nov 202511:01 amRNSNet Asset Value(s)
10th Oct 20252:27 pmRNSAuditor change
9th Oct 20254:08 pmRNSNet Asset Value(s)
3rd Oct 20257:02 amRNSNet Asset Value(s)
2nd Sep 20259:09 amRNSNet Asset Value(s)
4th Aug 202510:48 amRNSNet Asset Value(s)
25th Jul 20257:00 amRNSHalf-year Report
3rd Jul 20257:00 amRNSNet Asset Value(s)
3rd Jun 202512:08 pmRNSNet Asset Value(s)
6th May 20258:59 amRNSNet Asset Value(s)
24th Apr 20257:11 amRNSResult of the AGM
2nd Apr 20259:38 amRNSNet Asset Value(s)
11th Mar 20254:15 pmRNSAnnual Financial Report
4th Mar 202512:03 pmRNSNet Asset Value(s)
5th Feb 20258:01 amRNSNet Asset Value(s)
6th Jan 202510:25 amRNSNet Asset Value(s)
3rd Dec 20248:21 amRNSNet Asset Value(s)
4th Nov 20247:53 amRNSNet Asset Value(s)
10th Oct 20248:13 amRNSAuditor Appointment
3rd Oct 20241:29 pmRNSNet Asset Value(s)
4th Sep 20249:46 amRNSNet Asset Value(s)
16th Aug 20242:21 pmRNSChange of Adviser
2nd Aug 20247:46 amRNSNet Asset Value(s)
24th Jul 20242:03 pmRNSHalf-year Report
2nd Jul 202411:59 amRNSNet Asset Value(s)
6th Jun 20247:00 amRNSNet Asset Value(s)
7th May 20249:54 amRNSNet Asset Value(s)
4th Apr 20249:21 amRNSNet Asset Value(s)
22nd Mar 20248:15 amRNSAGM Statement
5th Mar 20242:04 pmRNSNet Asset Value(s)
13th Feb 202411:58 amRNSDividend Declaration
5th Feb 202410:17 amRNSNet Asset Value(s)
3rd Jan 202411:13 amRNSNet Asset Value(s)
5th Dec 20232:45 pmRNSNet Asset Value(s)
6th Nov 20237:00 amRNSNet Asset Value(s)
20th Oct 20237:29 amRNSAuditor appointment
10th Oct 202310:54 amRNSChange of Adviser
4th Oct 20232:58 pmRNSNet Asset Value(s)
4th Sep 202311:17 amRNSNet Asset Value(s)
2nd Aug 20239:06 amRNSNet Asset Value(s)
25th Jul 202311:37 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.